This document provides a 139-page report on global clinical trials for kidney cancer (renal cell cancer) in the second half of 2012. It includes data on the number and location of clinical trials, breakdown of trials by phase, status, subject recruitment, and leading sponsors. The report aims to give an overview of the clinical trial landscape and assess trends in research and development for treating kidney cancer worldwide.
Gastric Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on gastric cancer clinical trials in the second half of 2012. It includes 123 pages of data on over 1,000 clinical trials conducted globally, including information on the number and location of trials, participating companies and institutions, trial status and recruitment numbers. The report is available for purchase for $2,500 and provides detailed insight into ongoing and discontinued gastric cancer trials worldwide.
Endometrial Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a 107-page report on endometrial cancer clinical trials in the second half of 2012. It details the number of clinical trials conducted by region, country, phase, status, subjects recruited, and leading sponsors. The report aims to give an overview of the global clinical trial landscape for endometrial cancer and benchmark trial activity and trends over time. It is available for individual purchase at a price of $2,500.
Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on clinical trials for left ventricular dysfunction from 2012. It includes statistics on 97 clinical trials by region, country, phase, sponsor, and drug. The report gives an overview of trial recruitment status and numbers globally, and lists the top contributing countries, sponsors, and universities to left ventricular dysfunction trials in 2012.
The document provides an overview and analysis of clinical trials being conducted for ulcers on a global level in the first half of 2014. It summarizes the number of trials by region, with the most trials occurring in Asia-Pacific and Europe. The report also outlines the top countries contributing trials for each region and details clinical trials by phase, status, sponsor type, and recruited subjects over time. It concludes with profiles of prominent companies and institutions conducting ulcer trials.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Scientia Advisors Impact Of Microarray In M Dx Oct 2008glorikian
The document summarizes a report by Scientia Advisors on the impact of DNA microarrays on molecular diagnostics. It provides an overview of the microarray market for molecular diagnostics, which is currently small but growing rapidly. Key drivers of growth include the ability of microarrays to profile multiple genes and pathways involved in complex diseases like cancer. The document also discusses regulatory requirements, reimbursement challenges, examples of microarray-based diagnostic tests, and emerging array technologies that could increase clinical adoption if assay time, ease of use, and reproducibility are improved.
The kSORT assay to detect renal transplant patients at risk for acute rejecti...Kevin Jaglinski
Development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a critical need. In renal transplantation, acute rejection (AR) increases the risk for chronic graft injury and failure. Noninvasive diagnostic assays to improve current late and nonspecific diagnosis of rejection are needed. We sought to develop a test using a simple blood gene expression assay to detect patients at high risk for AR.
The kSORT Assay to Detect Renal Transplant Patients at High RiskKevin Jaglinski
This document describes a study that developed a blood gene expression assay called kSORT to detect renal transplant patients at high risk for acute rejection. Researchers analyzed gene expression data from over 500 blood samples across eight transplant centers. They selected a set of 17 genes that could detect acute rejection with high accuracy based on a training set of samples. This gene set was then validated on two independent sets of samples and could predict acute rejection up to 3 months before standard detection methods. A reference-based algorithm using the 17 genes was developed to provide a numerical risk score classifying patients as high or low risk for acute rejection. Overall, the kSORT assay provides a noninvasive tool for detecting acute rejection risk in renal transplant patients.
Gastric Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on gastric cancer clinical trials in the second half of 2012. It includes 123 pages of data on over 1,000 clinical trials conducted globally, including information on the number and location of trials, participating companies and institutions, trial status and recruitment numbers. The report is available for purchase for $2,500 and provides detailed insight into ongoing and discontinued gastric cancer trials worldwide.
Endometrial Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a 107-page report on endometrial cancer clinical trials in the second half of 2012. It details the number of clinical trials conducted by region, country, phase, status, subjects recruited, and leading sponsors. The report aims to give an overview of the global clinical trial landscape for endometrial cancer and benchmark trial activity and trends over time. It is available for individual purchase at a price of $2,500.
Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on clinical trials for left ventricular dysfunction from 2012. It includes statistics on 97 clinical trials by region, country, phase, sponsor, and drug. The report gives an overview of trial recruitment status and numbers globally, and lists the top contributing countries, sponsors, and universities to left ventricular dysfunction trials in 2012.
The document provides an overview and analysis of clinical trials being conducted for ulcers on a global level in the first half of 2014. It summarizes the number of trials by region, with the most trials occurring in Asia-Pacific and Europe. The report also outlines the top countries contributing trials for each region and details clinical trials by phase, status, sponsor type, and recruited subjects over time. It concludes with profiles of prominent companies and institutions conducting ulcer trials.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Scientia Advisors Impact Of Microarray In M Dx Oct 2008glorikian
The document summarizes a report by Scientia Advisors on the impact of DNA microarrays on molecular diagnostics. It provides an overview of the microarray market for molecular diagnostics, which is currently small but growing rapidly. Key drivers of growth include the ability of microarrays to profile multiple genes and pathways involved in complex diseases like cancer. The document also discusses regulatory requirements, reimbursement challenges, examples of microarray-based diagnostic tests, and emerging array technologies that could increase clinical adoption if assay time, ease of use, and reproducibility are improved.
The kSORT assay to detect renal transplant patients at risk for acute rejecti...Kevin Jaglinski
Development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a critical need. In renal transplantation, acute rejection (AR) increases the risk for chronic graft injury and failure. Noninvasive diagnostic assays to improve current late and nonspecific diagnosis of rejection are needed. We sought to develop a test using a simple blood gene expression assay to detect patients at high risk for AR.
The kSORT Assay to Detect Renal Transplant Patients at High RiskKevin Jaglinski
This document describes a study that developed a blood gene expression assay called kSORT to detect renal transplant patients at high risk for acute rejection. Researchers analyzed gene expression data from over 500 blood samples across eight transplant centers. They selected a set of 17 genes that could detect acute rejection with high accuracy based on a training set of samples. This gene set was then validated on two independent sets of samples and could predict acute rejection up to 3 months before standard detection methods. A reference-based algorithm using the 17 genes was developed to provide a numerical risk score classifying patients as high or low risk for acute rejection. Overall, the kSORT assay provides a noninvasive tool for detecting acute rejection risk in renal transplant patients.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
Cancer Genetics, Inc. is a personalized cancer diagnostics company that provides genomic testing services and proprietary diagnostic products. They have 5 commercially available diagnostic products that classify cancers like leukemia, lymphoma, kidney cancer, cervical cancer, and endometrial cancer. Their business model includes proprietary products, clinical cancer testing services, and clinical trial services. They aim to personalize cancer treatment by using biomarkers and genomic analysis to improve diagnosis, prognosis, and therapeutic selection compared to traditional methods.
This document provides an overview of Cancer Genetics, Inc.'s presentation at the RedChip Global Conference on October 15, 2014. The presentation discusses CGI's business focus on developing genomic tests to assess and personalize cancer treatment. It highlights six proprietary diagnostic products that have been commercially launched, as well as CGI's product pipeline. The presentation also summarizes CGI's partnerships with academic and research institutions and its global operations across multiple locations.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
This randomized controlled trial studied 198 patients having major cancer surgery who were assigned to either a restrictive or liberal red blood cell transfusion strategy. The restrictive strategy transfused patients when their hemoglobin was <7 g/dl, while the liberal strategy transfused at <9 g/dl. The primary outcome of death or major complications within 30 days occurred in 19.6% of the liberal group but 35.6% of the restrictive group, a statistically significant difference. A liberal transfusion strategy was associated with fewer complications. This study provides evidence that a more liberal transfusion approach may be preferable for patients having major cancer surgery.
1) CBCC was founded in 1984 in California as a small cancer clinic and has since expanded to become one of the largest cancer care providers in North America and India, operating multiple centers with over 30 oncologists and providing care and clinical trials to thousands of patients annually.
2) The document provides details on CBCC's centers and operations in the US and India, including locations, services, numbers of patients and clinical trials conducted across various cancer types.
3) CBCC has extensive experience conducting oncology clinical trials, with a focus on trials for breast, lung, ovarian and other cancers, and has participated in trials for many now-approved drugs through their affiliation with UCLA.
Pbio Investor Presentation Global Online Growth Conference - Oct 2016RedChip Companies, Inc.
This investor presentation discusses Pressure BioSciences, Inc. (PBIO), a company that develops and sells instruments and consumables for biological sample preparation using pressure cycling technology (PCT). The presentation provides an overview of PBIO's business, leadership, financials, and growth opportunities. Key points include PBIO having over 275 PCT systems installed, generating $1.8 million in revenue in 2015, closing a $5 million investment to strengthen its balance sheet, and partnering with SCIEX, a leader in mass spectrometry, to co-market PCT sample preparation solutions. The presentation outlines PBIO's focus on the estimated multi-billion dollar markets for sample preparation and mass spectrometry and its goal to achieve
Aga clinical practice update surgical risk assessment and perioperative manag...Hidert Chusi Huamani
This document provides guidance on surgical risk assessment and perioperative management for patients with cirrhosis undergoing surgical procedures. It discusses the unique pathophysiological risks of cirrhosis that can impact surgical outcomes. The Child-Turcotte-Pugh score and Model for End-Stage Liver Disease score are presented as tools to predict surgical risk, with the MELD score now preferred. Higher MELD scores, older age, and higher American Society of Anesthesiologists physical status classifications are associated with increased postoperative mortality. The risks vary depending on the urgency and type of surgery, with hepatobiliary surgery posing the highest risk. Careful patient selection and multidisciplinary management can help optimize outcomes.
LIRADS is a standardized system for interpreting and reporting findings of liver imaging to improve detection of hepatocellular carcinoma (HCC). It provides strict criteria and algorithms to categorize liver lesions identified on ultrasound, CT or MRI as definitely or probably benign (LR-1 to LR-3) or HCC (LR-4 to LR-5). The system aims to improve consistency and communication between radiologists and clinicians to help determine appropriate management. Major updates since 2011 have refined the diagnostic criteria and introduced algorithms for assessing treatment response to locoregional therapies for HCC. LIRADS is now integrated into American guidelines for diagnosis and treatment of HCC.
This document provides guidelines for the role of endoscopy in evaluating suspected choledocholithiasis (gallstones in the common bile duct). It recommends a risk-stratified approach based on initial evaluation. For low risk patients, only cholecystectomy is needed. For intermediate risk, additional imaging like EUS, MRCP or preoperative ERCP is recommended to further evaluate need for ductal stone removal. For high risk, preoperative ERCP or operative cholangiography is recommended due to frequent need for therapy. Non-endoscopic options like CT, MRCP, IOC and laparoscopic ultrasound are also discussed. The guidelines are meant to help endoscopists provide care while considering individual clinical factors.
The document discusses a study evaluating the use of The Paris System (TPS) for reporting urinary cytology specimens. The study reevaluated 46 urinary cytology specimens according to TPS criteria and found fair agreement between TPS categorizations and biopsy results. However, the study identified limitations in TPS criteria for evaluating specimen adequacy and diagnostic categories of atypical urothelial cells and low-grade urothelial neoplasia. The study concludes that revising these TPS criteria could help establish its more widespread use and improve communication between pathologists and clinicians.
This presentation summarizes Islet Sciences' strategy to address diabetes through early diagnosis, protection of insulin-producing cells, and transplantation of encapsulated porcine islets. Key points include developing a diagnostic test to detect beta cell DNA in blood to identify diabetes at an early stage, using Lysofylline to protect insulin cells from immune attack, and transplanting encapsulated pig islets to treat diabetes without immunosuppression. The company has partnerships with academic institutions and received grants to support its work. Financial statements show $3.5M in assets and $4.3M in liabilities as of January 2015.
This document discusses innovation and pre-clinical development in Brazil. It outlines characteristics of innovative countries, recent advances in science and technology in Brazil, and the growth of post-graduate programs. It then discusses the importance of pre-clinical studies like toxicology, pharmacokinetics, safety pharmacology, and local tolerance to support clinical trials. Finally, it introduces the Centre of Innovation and Pre-Clinical Studies, which aims to conduct pre-clinical research, support pharmaceutical development, and contribute to generating national competence in drug innovation.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
This investor presentation summarizes Pressure BioSciences' business and technology. PBI develops and sells instruments and consumables for sample preparation using its patented Pressure Cycling Technology platform. Key points include that PBI has over 275 PCT systems installed, has accomplished revenue growth and debt reduction in recent years, and signed a marketing agreement with SCIEX to co-promote its PCT-SWATH technology for mass spectrometry applications. The presentation outlines PBI's technology applications, market opportunities, customer base, and near-term growth drivers including the SCIEX partnership and new product releases.
WuXi AppTec's Laboratory Testing Division (LTD) provides fully integrated drug discovery and development testing solutions through eight major business platforms and over 2,000 employees across sites in China and the US. LTD is one of WuXi AppTec's largest divisions, contributing significantly to revenue and cash flow growth. It offers end-to-end services from discovery through clinical trials, leveraging synergies across businesses in discovery, preclinical, and clinical testing to support drug nomination and regulatory filings.
Aethlon Medical introduced HER2osomeTM, a novel medical device to inhibit HER2+ breast cancer progression. The device aims to simultaneously reduce HER2 protein and breast cancer exosomes in circulation, which are implicated in cancer growth, metastasis, and inhibiting drug effectiveness. To advance HER2osomeTM, Aethlon submitted a funding proposal to the Breast Cancer Research Program and will conduct pre-clinical and clinical studies. HER2osomeTM is based on Aethlon's ADAPTTM technology platform, which uses affinity agents immobilized on filters to selectively clear targets from blood without loss of other components or need for replacement fluids.
Development and internal validation of a multivariable prediction model for b...Max Peters
This document describes the development and internal validation of a prediction model for biochemical failure (BF) after salvage iodine-125 brachytherapy for recurrent prostate cancer. 62 patients who underwent salvage brachytherapy between 1993-2010 were studied. Multivariable analysis identified disease-free survival interval after primary therapy and pre-salvage prostate-specific antigen doubling time as predictors of BF, with higher intervals and doubling times associated with lower risk. The model had moderate discriminatory ability (optimism-adjusted C-statistic 0.70) and accurate calibration up to 36 months. Patients with doubling time >30 months and interval >60 months had >75% 3-year biochemical disease-free survival.
O documento resume as características da população brasileira discutidas em uma aula de geografia, incluindo a expectativa de vida (73,5 anos), a predominância feminina na população e a pirâmide etária que indica uma população envelhecendo. Também aborda o grau de escolaridade ainda baixo no Brasil e a distribuição da população economicamente ativa pelos setores primário, secundário e terciário.
O documento discute as dimensões críticas da qualidade que as empresas podem usar para competir, como atender às preferências dos clientes e ajustar a organização. Também aborda como a qualidade está relacionada a medidas de desempenho como custo, participação de mercado e lucratividade.
La lista proporciona traducciones entre palabras en español e inglés relacionadas con tamaños y descripciones físicas. Se traducen adjetivos como "alto", "bajo", "largo", "grande", "pequeño" y frases que describen ubicaciones y estados como "esta casa", "estos niños", "trabajo en esa oficina", "esas montañas".
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
Cancer Genetics, Inc. is a personalized cancer diagnostics company that provides genomic testing services and proprietary diagnostic products. They have 5 commercially available diagnostic products that classify cancers like leukemia, lymphoma, kidney cancer, cervical cancer, and endometrial cancer. Their business model includes proprietary products, clinical cancer testing services, and clinical trial services. They aim to personalize cancer treatment by using biomarkers and genomic analysis to improve diagnosis, prognosis, and therapeutic selection compared to traditional methods.
This document provides an overview of Cancer Genetics, Inc.'s presentation at the RedChip Global Conference on October 15, 2014. The presentation discusses CGI's business focus on developing genomic tests to assess and personalize cancer treatment. It highlights six proprietary diagnostic products that have been commercially launched, as well as CGI's product pipeline. The presentation also summarizes CGI's partnerships with academic and research institutions and its global operations across multiple locations.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
This randomized controlled trial studied 198 patients having major cancer surgery who were assigned to either a restrictive or liberal red blood cell transfusion strategy. The restrictive strategy transfused patients when their hemoglobin was <7 g/dl, while the liberal strategy transfused at <9 g/dl. The primary outcome of death or major complications within 30 days occurred in 19.6% of the liberal group but 35.6% of the restrictive group, a statistically significant difference. A liberal transfusion strategy was associated with fewer complications. This study provides evidence that a more liberal transfusion approach may be preferable for patients having major cancer surgery.
1) CBCC was founded in 1984 in California as a small cancer clinic and has since expanded to become one of the largest cancer care providers in North America and India, operating multiple centers with over 30 oncologists and providing care and clinical trials to thousands of patients annually.
2) The document provides details on CBCC's centers and operations in the US and India, including locations, services, numbers of patients and clinical trials conducted across various cancer types.
3) CBCC has extensive experience conducting oncology clinical trials, with a focus on trials for breast, lung, ovarian and other cancers, and has participated in trials for many now-approved drugs through their affiliation with UCLA.
Pbio Investor Presentation Global Online Growth Conference - Oct 2016RedChip Companies, Inc.
This investor presentation discusses Pressure BioSciences, Inc. (PBIO), a company that develops and sells instruments and consumables for biological sample preparation using pressure cycling technology (PCT). The presentation provides an overview of PBIO's business, leadership, financials, and growth opportunities. Key points include PBIO having over 275 PCT systems installed, generating $1.8 million in revenue in 2015, closing a $5 million investment to strengthen its balance sheet, and partnering with SCIEX, a leader in mass spectrometry, to co-market PCT sample preparation solutions. The presentation outlines PBIO's focus on the estimated multi-billion dollar markets for sample preparation and mass spectrometry and its goal to achieve
Aga clinical practice update surgical risk assessment and perioperative manag...Hidert Chusi Huamani
This document provides guidance on surgical risk assessment and perioperative management for patients with cirrhosis undergoing surgical procedures. It discusses the unique pathophysiological risks of cirrhosis that can impact surgical outcomes. The Child-Turcotte-Pugh score and Model for End-Stage Liver Disease score are presented as tools to predict surgical risk, with the MELD score now preferred. Higher MELD scores, older age, and higher American Society of Anesthesiologists physical status classifications are associated with increased postoperative mortality. The risks vary depending on the urgency and type of surgery, with hepatobiliary surgery posing the highest risk. Careful patient selection and multidisciplinary management can help optimize outcomes.
LIRADS is a standardized system for interpreting and reporting findings of liver imaging to improve detection of hepatocellular carcinoma (HCC). It provides strict criteria and algorithms to categorize liver lesions identified on ultrasound, CT or MRI as definitely or probably benign (LR-1 to LR-3) or HCC (LR-4 to LR-5). The system aims to improve consistency and communication between radiologists and clinicians to help determine appropriate management. Major updates since 2011 have refined the diagnostic criteria and introduced algorithms for assessing treatment response to locoregional therapies for HCC. LIRADS is now integrated into American guidelines for diagnosis and treatment of HCC.
This document provides guidelines for the role of endoscopy in evaluating suspected choledocholithiasis (gallstones in the common bile duct). It recommends a risk-stratified approach based on initial evaluation. For low risk patients, only cholecystectomy is needed. For intermediate risk, additional imaging like EUS, MRCP or preoperative ERCP is recommended to further evaluate need for ductal stone removal. For high risk, preoperative ERCP or operative cholangiography is recommended due to frequent need for therapy. Non-endoscopic options like CT, MRCP, IOC and laparoscopic ultrasound are also discussed. The guidelines are meant to help endoscopists provide care while considering individual clinical factors.
The document discusses a study evaluating the use of The Paris System (TPS) for reporting urinary cytology specimens. The study reevaluated 46 urinary cytology specimens according to TPS criteria and found fair agreement between TPS categorizations and biopsy results. However, the study identified limitations in TPS criteria for evaluating specimen adequacy and diagnostic categories of atypical urothelial cells and low-grade urothelial neoplasia. The study concludes that revising these TPS criteria could help establish its more widespread use and improve communication between pathologists and clinicians.
This presentation summarizes Islet Sciences' strategy to address diabetes through early diagnosis, protection of insulin-producing cells, and transplantation of encapsulated porcine islets. Key points include developing a diagnostic test to detect beta cell DNA in blood to identify diabetes at an early stage, using Lysofylline to protect insulin cells from immune attack, and transplanting encapsulated pig islets to treat diabetes without immunosuppression. The company has partnerships with academic institutions and received grants to support its work. Financial statements show $3.5M in assets and $4.3M in liabilities as of January 2015.
This document discusses innovation and pre-clinical development in Brazil. It outlines characteristics of innovative countries, recent advances in science and technology in Brazil, and the growth of post-graduate programs. It then discusses the importance of pre-clinical studies like toxicology, pharmacokinetics, safety pharmacology, and local tolerance to support clinical trials. Finally, it introduces the Centre of Innovation and Pre-Clinical Studies, which aims to conduct pre-clinical research, support pharmaceutical development, and contribute to generating national competence in drug innovation.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
This investor presentation summarizes Pressure BioSciences' business and technology. PBI develops and sells instruments and consumables for sample preparation using its patented Pressure Cycling Technology platform. Key points include that PBI has over 275 PCT systems installed, has accomplished revenue growth and debt reduction in recent years, and signed a marketing agreement with SCIEX to co-promote its PCT-SWATH technology for mass spectrometry applications. The presentation outlines PBI's technology applications, market opportunities, customer base, and near-term growth drivers including the SCIEX partnership and new product releases.
WuXi AppTec's Laboratory Testing Division (LTD) provides fully integrated drug discovery and development testing solutions through eight major business platforms and over 2,000 employees across sites in China and the US. LTD is one of WuXi AppTec's largest divisions, contributing significantly to revenue and cash flow growth. It offers end-to-end services from discovery through clinical trials, leveraging synergies across businesses in discovery, preclinical, and clinical testing to support drug nomination and regulatory filings.
Aethlon Medical introduced HER2osomeTM, a novel medical device to inhibit HER2+ breast cancer progression. The device aims to simultaneously reduce HER2 protein and breast cancer exosomes in circulation, which are implicated in cancer growth, metastasis, and inhibiting drug effectiveness. To advance HER2osomeTM, Aethlon submitted a funding proposal to the Breast Cancer Research Program and will conduct pre-clinical and clinical studies. HER2osomeTM is based on Aethlon's ADAPTTM technology platform, which uses affinity agents immobilized on filters to selectively clear targets from blood without loss of other components or need for replacement fluids.
Development and internal validation of a multivariable prediction model for b...Max Peters
This document describes the development and internal validation of a prediction model for biochemical failure (BF) after salvage iodine-125 brachytherapy for recurrent prostate cancer. 62 patients who underwent salvage brachytherapy between 1993-2010 were studied. Multivariable analysis identified disease-free survival interval after primary therapy and pre-salvage prostate-specific antigen doubling time as predictors of BF, with higher intervals and doubling times associated with lower risk. The model had moderate discriminatory ability (optimism-adjusted C-statistic 0.70) and accurate calibration up to 36 months. Patients with doubling time >30 months and interval >60 months had >75% 3-year biochemical disease-free survival.
O documento resume as características da população brasileira discutidas em uma aula de geografia, incluindo a expectativa de vida (73,5 anos), a predominância feminina na população e a pirâmide etária que indica uma população envelhecendo. Também aborda o grau de escolaridade ainda baixo no Brasil e a distribuição da população economicamente ativa pelos setores primário, secundário e terciário.
O documento discute as dimensões críticas da qualidade que as empresas podem usar para competir, como atender às preferências dos clientes e ajustar a organização. Também aborda como a qualidade está relacionada a medidas de desempenho como custo, participação de mercado e lucratividade.
La lista proporciona traducciones entre palabras en español e inglés relacionadas con tamaños y descripciones físicas. Se traducen adjetivos como "alto", "bajo", "largo", "grande", "pequeño" y frases que describen ubicaciones y estados como "esta casa", "estos niños", "trabajo en esa oficina", "esas montañas".
Beat the Clock: Finding the Gremlins Behind Slow Mobile Page LoadsKeynote Mobile Testing
The document discusses the importance of fast page loads on mobile and identifies 10 common "gremlins" that can slow down mobile page speeds. These gremlins include having too many HTTP requests, domains, serial downloads, slow initial renders, unnecessary redirections, inefficient third-party calls, images, lack of caching, non-persistent TCP connections, and unnecessary SSL. The document emphasizes that speed is critical for mobile as customers expect instant page loads and will abandon sites that are too slow. Organizations must prioritize performance, use tools to monitor and diagnose issues, and follow best practices to optimize page speeds and beat these gremlins.
Ireland Anesthesia and Respiratory Devices Investment Opportunities, Analysis...ReportsnReports
The document provides a 218-page report on investment opportunities in anesthesia and respiratory devices in Ireland from 2012-2018. It includes market size data in revenue, volume, and price for various device categories from 2004-2011 with forecasts to 2018. The report also provides company market share data and profiles key companies operating in the Irish market. It aims to help readers develop business and market strategies for strong growth areas in the Irish anesthesia and respiratory devices industry.
Europe Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxill...ReportsnReports
This report provides a summary of the Europe Orthopedic Devices market outlook from 2004-2018. It analyzes market revenue and company shares across key categories like knee reconstruction, hip reconstruction, and spinal surgery in major European countries. The 282-page report was published in August 2012 and sells for a single user license of $3,500. It draws data from proprietary databases and research to provide an overview of market sizes, trends, and major players in the European orthopedic devices industry.
The document presents two solutions for secure internet banking authentication - one based on short-time passwords using hardware security modules, and the other based on certificate-based authentication using smart cards. It discusses current authentication threats like offline credential stealing and online channel breaking attacks. Both proposed solutions offer strong security against these common attacks, with the certificate-based solution being highly attractive for the future due to changing legislation and potential widespread use of electronic IDs.
Индивидуальное продвижение - шаг в сторону продвижения по лидамMegaIndexTV
Выступление Даниэла Херени на конференции SEO Moscow 2011
http://www.megaindex.tv/programs/seo_moscow_2011/individualnoe_prodvizhenie__shag_v_storonu_prodvizheniya_po_lidam/
- Jordan, Luke, Jake, and James want to grow their businesses but are facing challenges hiring new salespeople.
- My Company is proposing to build a custom "Referral Engine" using each company's customer base and strategic partners to generate leads and opportunities, acting as a sales team.
- The Referral Engine will work to cultivate leads and opportunities from the existing customer community and strategic partnerships both online and offline.
UCSF CER - Comparative Effectiveness Program (Symposium 2013)CTSI at UCSF
The UCSF CTSI Comparative Effectiveness Research Program aims to catalyze CER studies and grant proposals by investigators through developing its own resources and serving as a bridge to existing UCSF programs relevant to CER. The program maintains a listserv to share funding announcements, field developments, and educational opportunities. It also convenes experts, builds partnerships within the Bay Area, and represents UCSF in the CTSA consortium to collaborate on initiatives like registries, data networks, and symposia. Relevant resources and programs can be found on the program's website.
This document provides a summary of a 942-page report on dermatology partnering terms and agreements from 2007 to 2012. The report details trends in big pharmaceutical company dealmaking in dermatology, including deal structures, financial terms, and over 1,500 links to actual deals and contracts. It analyzes headline values, upfront payments, milestone payments, and royalty rates by development stage. The report is intended to help readers understand and access trends in dermatology partnering and dealmaking.
Social Flavour Qual é o seu? é uma coletânea dos melhores infográficos sobre redes sociais, abordando temas como perfis de usuários, tendências e como as plataformas estão moldando a sociedade.
United States Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio...ReportsnReports
This report provides an in-depth analysis of the US orthopedic devices market from 2004-2018. It covers market size, trends, segmentation, and company profiles for 12 device categories including trauma fixation, knee reconstruction, hip reconstruction and more. Key findings include that the overall US orthopedic devices market is expected to grow from $16.7 billion in 2011 to $22.1 billion in 2018. Major players like Stryker, DePuy, Medtronic, Zimmer and Smith & Nephew dominate market share across categories. The 433-page report provides detailed historical and forecasted revenue/volume/price data with insights to help companies develop business strategies for orthopedic device segments.
Argentina In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Gen...ReportsnReports
This report provides an in-depth analysis of the in vitro diagnostics market in Argentina from 2004-2018. It segments the market into seven categories - clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. For each segment, the report provides historical revenue data from 2004-2011 and forecasts revenue from 2011-2018. It also analyzes the market share of major companies operating in each segment of the Argentina in vitro diagnostics market. The 254-page report is based on proprietary databases and primary/secondary research.
O documento descreve três valências de um centro comunitário destinadas a diferentes faixas etárias: a valência "Porta Aberta" para crianças dos 6 aos 12 anos com atividades lúdico-pedagógicas; o "Klube de Jovens" para jovens dos 13 aos 18 anos com experiências desportivas e debates; e o grupo "Tesouros de Vida" para idosos com atividades de combate ao isolamento social como convívios e cursos.
Liver Fibrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
Liver Fibrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Liver Fibrosis Global Clinical Trials Review, H1, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Coronary Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Coronary Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report from GlobalData on clinical trials for abdominal aortic aneurysms. The report provides data on over 100 clinical trials conducted between 2007-2012, including regional breakdown of trials, top sponsoring companies and universities, prominent drugs being tested, and trends in trial enrollment numbers over time. The report aims to give readers an overview of experimental treatments and global research activity for abdominal aortic aneurysms.
Congenital Heart Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Congenital Heart Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Congenital Heart Disease Global Clinical Trials Review, H1, 2012" provides data on the Congenital Heart Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congenital Heart Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congenital Heart Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Sezary Syndrome Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Sezary Syndrome from January 2013. It provides an overview of the number and location of trials worldwide. The report details trials by region, country, phase, status, subjects recruited, and prominent sponsors. It also profiles the top companies and universities/institutes conducting Sezary Syndrome trials.
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Oncology Intelligence Report 2014 (Table of contents)OmicsX
Oncology Drug Report 2014 –World’s Largest Active Resource for Decision Making, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.
For Details Visit :- https://omicsx.com/reports/cancer/oncology-intelligence-report-2014/
Acute Lung Injury Global Clinical Trials Review, H2, 2012ReportLinker.com
Acute Lung Injury Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Acute Lung Injury Global Clinical Trials Review, H2, 2012" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
Anal Fissure Global Clinical Trials Review, H1, 2013ReportLinker.com
Anal Fissure Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Anal Fissure Global Clinical Trials Review, H1, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Bladder Cancer Diagnostic-Initial Team ProjectSagar Desai
ACDS Laboratories has developed a new 3-protein biomarker for bladder cancer diagnosis using VEGF, ApoE, and IL-8. The biomarker provides high sensitivity of 90% and specificity of 97% in a study of 127 patients, outperforming current methods. It can be detected through a non-invasive urine test using ELISA, addressing the need for a simple, accurate, and cost-effective diagnostic. Economic analysis shows the biomarker could save over $200 million annually in the US through reducing invasive procedures and long-term monitoring costs compared to current protocols. Based on the strong clinical and economic value, ACDS recommends investing in developing this biomarker.
Asperger Syndrome Global Clinical Trials Review, H2, 2012ReportLinker.com
Asperger Syndrome Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Asperger Syndrome Global Clinical Trials Review, H2, 2012" provides data on the Asperger Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Asperger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Asperger Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Dr. Kelvin Chan gave a short explanation on what real-world evidence (RWE) is, how they can be used in cancer care and what benefits patients can get from the real-world evidence. He will also introduce the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which is a pan-Canadian collaboration working on developing a framework to generate and use real-world evidence to inform cancer drug funding decisions.
The webinar was followed by an interactive question & answer session.
PRA Health Sciences is a leader in conducting global oncology and hematology clinical trials. Over the past 5 years, PRA has participated in over 400 oncology and hematology projects involving over 47,000 patients across 9,200 clinical sites. They leverage evidence-based approaches and their network of over 50 in-house oncology experts to efficiently design and execute trials that advance the development of new drugs and therapies for cancer patients.
Filariasis Global Clinical Trials Review, H1, 2013ReportLinker.com
Filariasis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Filariasis Global Clinical Trials Review, H1, 2013" provides data on the Filariasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Filariasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Filariasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Similar to Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012 (20)
Filariasis Global Clinical Trials Review, H1, 2013
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012
1. Kidney Cancer (Renal Cell Cancer) Global Clinical Trials
Review, H2, 2012
Report Details:
Published:December 2012
No. of Pages: 139
Price: Single User License – US$2500
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012
Summary
GlobalData''s clinical trial report, “Kidney Cancer (Renal Cell Cancer) Global Clinical Trials
Review, H2, 2012" provides data on the Kidney Cancer (Renal Cell Cancer) clinical trial scenario.
This report provides elemental information and data relating to the clinical trials on Kidney Cancer
(Renal Cell Cancer). It includes an overview of the trial numbers and their recruitment status as
per the site of trial conduction across the globe. The databook offers a preliminary coverage of
disease clinical trials by their phase, trial status, prominence of the sponsors and also provides
briefing pertaining to the number of trials for the key drugs for treating Kidney Cancer (Renal Cell
Cancer). This report is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GlobalData''s team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America,
Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along
with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and
sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
2. - Abridged view of the performance of the trials in terms of their status, recruitment, location,
sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Get your copy of this report @
http://www.reportsnreports.com/reports/210604-kidney-cancer-renal-cell-cancer-global-clinical-trials-review-h2-
2012.html
Major points covered in Table of Contents of this report include
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Kidney Cancer (Renal Cell Cancer) 8
Report Guidance 8
Clinical Trials by Region 9
Clinical Trials by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by BRIC Nations 17
Clinical Trials by G7 Nations 18
Clinical Trials in G7 Nations by Trial Status 19
Clinical Trials by E7 Nations 20
Clinical Trials in E7 Nations by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Unaccomplished Trials of Kidney Cancer (Renal Cell Cancer) 25
Subjects Recruited Over a Period of Time 35
Prominent Sponsors 36
Top Companies Participating in Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials 38
Prominent Drug Comparison 40
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
Pfizer Inc. 41
Clinical Trial Overview of Pfizer Inc. 41
Bayer AG 45
Clinical Trial Overview of Bayer AG 45
3. GlaxoSmithKline plc 47
Clinical Trial Overview of GlaxoSmithKline plc 47
Novartis AG 49
Clinical Trial Overview of Novartis AG 49
Bristol-Myers Squibb Company 51
Clinical Trial Overview of Bristol-Myers Squibb Company 51
Eli Lilly and Company 52
Clinical Trial Overview of Eli Lilly and Company 52
Amgen Inc. 53
Clinical Trial Overview of Amgen Inc. 53
AVEO Pharmaceuticals, Inc. 54
Clinical Trial Overview of AVEO Pharmaceuticals, Inc. 54
Argos Therapeutics, Inc. 55
Clinical Trial Overview of Argos Therapeutics, Inc. 55
Pierre Fabre Medicament 56
Clinical Trial Overview of Pierre Fabre Medicament 56
Abbott Laboratories 57
Clinical Trial Overview of Abbott Laboratories 57
AstraZeneca PLC 58
Clinical Trial Overview of AstraZeneca PLC 58
Agenus, Inc. 59
Clinical Trial Overview of Agenus, Inc. 59
Genentech, Inc. 60
Clinical Trial Overview of Genentech, Inc. 60
Seattle Genetics, Inc. 61
Clinical Trial Overview of Seattle Genetics, Inc. 61
Hoffmann-La Roche Inc. 62
Clinical Trial Overview of Hoffmann-La Roche Inc. 62
F. Hoffmann-La Roche Ltd. 63
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 63
Oxford BioMedica plc 64
Clinical Trial Overview of Oxford BioMedica plc 64
Celgene Corporation 65
Clinical Trial Overview of Celgene Corporation 65
Novartis Pharmaceuticals Corporation 66
Clinical Trial Overview of Novartis Pharmaceuticals Corporation 66
Clinical Trial Overview of Top Universities / Institutes / Hospitals 67
Memorial Sloan Kettering Cancer Center 67
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 67
The University of Texas M. D. Anderson Cancer Center 71
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 71
UCLA''s Jonsson Comprehensive Cancer Center 74
4. Clinical Trial Overview of UCLA''s Jonsson Comprehensive Cancer Center 74
Case Comprehensive Cancer Center 76
Clinical Trial Overview of Case Comprehensive Cancer Center 76
The University of Chicago 77
Clinical Trial Overview of The University of Chicago 77
Roswell Park Cancer Institute 78
Clinical Trial Overview of Roswell Park Cancer Institute 78
Beth Israel Deaconess Medical Center 79
Clinical Trial Overview of Beth Israel Deaconess Medical Center 79
Radboud University 80
Clinical Trial Overview of Radboud University 80
Barbara Ann Karmanos Cancer Institute 81
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 81
Wake Forest University 82
Clinical Trial Overview of Wake Forest University 82
Fred Hutchinson Cancer Research Center 83
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 83
Sarah Cannon Research Institute 84
Clinical Trial Overview of Sarah Cannon Research Institute 84
Mayo Clinic 85
Clinical Trial Overview of Mayo Clinic 85
Masonic Cancer Center 86
Clinical Trial Overview of Masonic Cancer Center 86
University Health Network 87
Clinical Trial Overview of University Health Network 87
Dana-Farber Cancer Institute 88
Clinical Trial Overview of Dana-Farber Cancer Institute 88
Fox Chase Cancer Center 89
Clinical Trial Overview of Fox Chase Cancer Center 89
Duke University 90
Clinical Trial Overview of Duke University 90
The Methodist Hospital System 91
Clinical Trial Overview of The Methodist Hospital System 91
University of California, San Francisco 92
Clinical Trial Overview of University of California, San Francisco 92
Five Key Clinical Profiles 93
Appendix 136
Abbreviations 136
Definitions 136
Research Methodology 137
Secondary Research 137
About GlobalData 138
5. Contact Us 138
Disclaimer 138
Source 139
List of Tables
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Zone, 2012* 9
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Top Countries,
2012* 10
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials In Progress by
Top Countries, 2012* 11
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries,
2012* 12
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries,
2012* 13
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries,
2012* 14
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five
Countries, 2012* 15
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top
Five Countries, 2012* 16
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, BRIC Countries, 2012* 17
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, G7 Countries, 2012* 18
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, G7 Countries, Clinical Trials by Trial
Status, 2012* 19
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, E7 Countries, 2012* 20
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, E7 Countries, Clinical Trials by Trial
Status, 2012* 21
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Phase, 2012*
22
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials In Progress by
Phase 2012* 23
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Trial Status,
2012* 24
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Suspended Clinical Trials, 2012*
25
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Withdrawn Clinical Trials, 2012*
26
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Terminated Clinical Trials, 2012*
28
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment
Target Trends, 2006-2011 35
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 37
6. Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by
Phase, 2012* 39
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Clinical Trials by
Prominent Drugs, 2012* 40
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Pfizer Inc., 2012* 41
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Bayer AG, 2012* 45
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
GlaxoSmithKline plc, 2012* 47
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Novartis AG, 2012* 49
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Bristol-Myers Squibb Company, 2012* 51
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Eli Lilly and Company, 2012* 52
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Amgen Inc., 2012* 53
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
AVEO Pharmaceuticals, Inc., 2012* 54
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Argos Therapeutics, Inc., 2012* 55
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Pierre Fabre Medicament, 2012* 56
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Abbott Laboratories, 2012* 57
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
AstraZeneca PLC, 2012* 58
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Agenus, Inc., 2012* 59
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Genentech, Inc., 2012* 60
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Seattle Genetics, Inc., 2012* 61
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Hoffmann-La Roche Inc., 2012* 62
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
F. Hoffmann-La Roche Ltd., 2012* 63
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Oxford BioMedica plc, 2012* 64
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Celgene Corporation, 2012* 65
7. Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Novartis Pharmaceuticals Corporation, 2012* 66
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Memorial Sloan Kettering Cancer Center, 2012* 67
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
The University of Texas M. D. Anderson Cancer Center, 2012* 71
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
UCLA''s Jonsson Comprehensive Cancer Center, 2012* 74
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Case Comprehensive Cancer Center, 2012* 76
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
The University of Chicago, 2012* 77
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Roswell Park Cancer Institute, 2012* 78
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Beth Israel Deaconess Medical Center, 2012* 79
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Radboud University, 2012* 80
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Barbara Ann Karmanos Cancer Institute, 2012* 81
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Wake Forest University, 2012* 82
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Fred Hutchinson Cancer Research Center, 2012* 83
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Sarah Cannon Research Institute, 2012* 84
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Mayo Clinic, 2012* 85
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Masonic Cancer Center, 2012* 86
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
University Health Network, 2012* 87
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Dana-Farber Cancer Institute, 2012* 88
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Fox Chase Cancer Center, 2012* 89
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
Duke University, 2012* 90
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
The Methodist Hospital System, 2012* 91
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by
University of California, San Francisco, 2012* 92
8. List of Figures
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Zone (%),
2012* 9
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Top Countries,
2012* 10
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials In Progress by
Top Countries, 2012* 11
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries
(%), 2012* 12
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%),
2012* 13
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries
(%), 2012* 14
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five
Countries (%), 2012* 15
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top
Five Countries (%), 2012* 16
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, BRIC Countries (%), 2012* 17
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, G7 Countries (%), 2012* 18
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, G7 Countries, Clinical Trials by Trial
Status, 2012* 19
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, E7 Countries (%), 2012* 20
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, E7 Countries, Clinical Trials by Trial
Status, 2012* 21
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Phase (%),
2012* 22
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials In Progress by
Phase, 2012* 23
Kidney Cancer (Renal Cell Cancer) Therapeutics Market, Global, Clinical Trials by Trial Status,
2012* 24
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment
Target Trends, 2006-2011 35
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 36
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by
Phase, 2012* 38
Kidney Cancer (Renal Cell Cancer) Therapeutics Clinical Trials, Global, Clinical Trials by
Prominent Drugs, 2012* 40
GlobalData Methodology 137
Contact: sales@reportsandreports.com for more information.